Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for lopinavir (A02.001 inhibitor)

Summary Structure Literature

(Topics flags: A Assay, S Structure, M Mutation, I Inhibitor, E Expression, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

    2020
  1. Jean,S.S., Lee,P.I. and Hsueh,P.R.<br>Treatment options for COVID-19: The reality and challenges<br>J Microbiol Immunol Infect (2020) 53, 436-443. PubMed  Europe PubMed DOI  PMC  EPMC  I
    2. 2019
  2. Khan,A.A., Mudassir,J., Akhtar,S., Murugaiyah,V. and Darwis,Y.<br>Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations<br>Pharmaceutics (2019) 11 PubMed  Europe PubMed DOI  I
  3. Paskas,S., Mazzon,E., Basile,M.S., Cavalli,E., Al-Abed,Y., He,M., Rakocevic,S., Nicoletti,F., Mijatovic,S. and Maksimovic-Ivanic,D.<br>Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo<br>Invest New Drugs (2019) 37, 1014-1028. PubMed  Europe PubMed DOI  I
  4. Schwake,C., Baldwin,M.R., Bachovchin,W., Hegde,S., Schiemer,J., Okure,C., Levin,A.E., Vannier,E., Hanada,T. and Chishti,A.H.<br>HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes<br>Biochem Biophys Res Commun (2019) 517, 125-131. PubMed  Europe PubMed DOI  I
    5. 2018
  5. Alvarenga,D.L.R., Silva,A.H.D.S., Fiuza,J.A., Gaze,S.T., de Oliveira,J.G., Oliveira,R.C., Calzavara-Silva,C.E., Pascoal-Xavier,M.A. and Alves,E.A.R.<br>HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis<br>Int Immunopharmacol (2018) 60, 179-188. PubMed  Europe PubMed DOI  I
  6. Onchieku,N.M., Mogire,R., Ndung'u,L., Mwitari,P., Kimani,F., Matoke-Muhia,D., Kiboi,D. and Magoma,G.<br>Deciphering the targets of retroviral protease inhibitors in Plasmodium berghei<br>PLoS ONE (2018) 13, e0201556-e0201556. PubMed  Europe PubMed DOI  PMC  EPMC  I
    7. 2017
  7. Clark,K.M., Jenkins,J.L., Fedoriw,N. and Dumont,M.E.<br>Human CaaX protease ZMPSTE24 expressed in yeast: structure and inhibition by HIV protease inhibitors<br>Protein Sci (2017) 26, 242-257. PubMed  Europe PubMed DOI  E  S  I
    8. 2015
  8. El Hoss,S., Bahr,G.M. and Echtay,K.S.<br>Lopimune-Induced mitochondrial toxicity is attenuated by increased uncoupling protein-2 level in treated mouse hepatocytes<br>Biochem J (2015) 468, 401-407. PubMed  Europe PubMed DOI  I
  9. Li,N., Ainsworth,R.I., Ding,B., Hou,T. and Wang,W.<br>Using hierarchical virtual screening to combat drug resistance of the HIV-1 protease<br>J Chem Inf Model (2015) 55, 1400-1412. PubMed  Europe PubMed DOI  I
    10. 2014
  10. Yedidi,R.S., Liu,Z., Kovari,I.A., Woster,P.M. and Kovari,L.C.<br>P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease<br>J Mol Graph Model (2014) 47, 18-24. PubMed  Europe PubMed DOI  I
    11. 2012
  11. Bartlett,J.A., Ribaudo,H.J., Wallis,C.L., Aga,E., Katzenstein,D.A., Stevens,W.S., Norton,M.R., Klingman,K.L., Hosseinipour,M.C., Crump,J.A., Supparatpinyo,K., Badal-Faesen,S., Kallungal,B.A. and Kumarasamy,N.<br>Lopinavir/ritonavir Monotherapy After Virologic Failure of First-line Antiretroviral Therapy in Resource-limited Settings<br>AIDS (2012) 26, 1345-1354. PubMed  Europe PubMed DOI  I
  12. Capel,E., Auclair,M., Caron-Debarle,M. and Capeau,J.<br>Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes<br>Antivir Ther (2012) 17, 549-556. PubMed  Europe PubMed DOI  I
  13. Kou,H., Ye,M., Fu,Q., Han,Y., Du,X., Xie,J., Zhu,Z. and Li,T.<br>Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection<br>Sci China Life Sci (2012) 55, 321-327. PubMed  Europe PubMed DOI  A  I
  14. Santos,J.R., Llibre,J.M., Imaz,A., Domingo,P., Iribarren,J.A., Marino,A., Miralles,C., Galindo,M.J., Ornelas,A., Moreno,S., Schapiro,J.M. and Clotet,B.<br>Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens<br>J Antimicrob Chemother (2012) 67, 1462-1469. PubMed  Europe PubMed DOI  I
    15. 2011
  15. Lin,Y.C., Perryman,A.L., Olson,A.J., Torbett,B.E., Elder,J.H. and Stout,C.D.<br>Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease<br>Acta Crystallogr D Biol Crystallogr (2011) 67, 540-548. PubMed  Europe PubMed DOI  S  I
  16. Magiorkinis,E., Paraskevis,D., Detsika,M.G., Lu,L., Magiorkinis,G., Lazanas,M., Imbrechts,S., Van Laethem,K., Vandamme,A.M., Pilot-Matias,T., Molla,A., Camacho,R.J. and Hatzakis,A.<br>Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility<br>AIDS Res Hum Retroviruses (2011) 27, 1223-1229. PubMed  Europe PubMed DOI  M  I
  17. Vats,R., Murthy,A.N. and Ravi,P.R.<br>Simple, rapid and validated LC determination of lopinavir in rat plasma and its application in pharmacokinetic studies<br>Sci Pharm (2011) 79, 849-863. PubMed  Europe PubMed DOI  PMC  EPMC  I
    18. 2010
  18. Wensing,A.M., van Maarseveen,N.M. and Nijhuis,M.<br>Fifteen years of HIV protease inhibitors: raising the barrier to resistance<br>Antiviral Res (2010) 85, 59-74. PubMed  Europe PubMed DOI  V  I
    19. 2008
  19. Bhaskar,G., Kumar,A.R., Ramu,E. and Rao,B.V.<br>Synthesis of a hydroxyethylene dipeptide isostere, a core unit of the HIV protease inhibitors ritonavir and lopinavir, and its C-5 epimer<br>Synthesis (Stuttgart) (2008) 2008, 3061-3064. DOI  I
  20. Chandwani,A. and Shuter,J.<br>Lopinavir/ritonavir in the treatment of HIV-1 infection: a review<br>Ther Clin Risk Manag (2008) 4, 1023-1033. PubMed  Europe PubMed  PMC  EPMC  I
  21. Coffinier,C., Hudon,S.E., Lee,R., Farber,E.A., Nobumori,C., Miner,J.H., Andres,D.A., Spielmann,H.P., Hrycyna,C.A., Fong,L.G. and Young,S.G.<br>A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells<br>J Biol Chem (2008) 283, 9797-9804. PubMed  Europe PubMed DOI  PMC  EPMC  I
  22. Nukoolkarn,V., Lee,V.S., Malaisree,M., Aruksakulwong,O. and Hannongbua,S.<br>Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors<br>J Theor Biol (2008) 254, 861-867. PubMed  Europe PubMed DOI  I
  23. Saskova,K.G., Kozisek,M., Lepsik,M., Brynda,J., Rezacova,P., Vaclavikova,J., Kagan,R.M., Machala,L. and Konvalinka,J.<br>Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir<br>Protein Sci (2008) 17, 1555-1564. PubMed  Europe PubMed DOI  PMC  EPMC  S  I
    24. 2007
  24. Tan,D. and Walmsley,S.<br>Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections<br>Expert Rev Anti Infect Ther (2007) 5, 13-28. PubMed  Europe PubMed DOI  I
    25. 2006
  25. Andrews,K.T., Fairlie,D.P., Madala,P.K., Ray,J., Wyatt,D.M., Hilton,P.M., Melville,L.A., Beattie,L., Gardiner,D.L., Reid,R.C., Stoermer,M.J., Skinner-Adams,T., Berry,C. and McCarthy,J.S.<br>Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria<br>Antimicrob Agents Chemother (2006) 50, 639-648. PubMed  Europe PubMed DOI  PMC  EPMC  I
  26. [YEAR:24-4-2006]de Mendoza,C., Valer,L., Bacheler,L., Pattery,T., Corral,A. and Soriano,V.<br>Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance<br>AIDS (24-4-2006) 20, 1071-1074. PubMed  Europe PubMed DOI  I
  27. Mastrolorenzo,A., Rusconi,S., Scozzafava,A. and Supuran,C.T.<br>Inhibitors of HIV-1 protease: 10 years after<br>Expert Opin Ther Pat (2006) 16, 1067-1091. DOI  V  I
  28. [YEAR:2-1-2006]Rodes,B., Toro,C., Sheldon,J.A., Jimenez,V., Mansinho,K. and Soriano,V.<br>High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART<br>AIDS (2-1-2006) 20, 127-129. PubMed  Europe PubMed  I
    29. 2005
  29. [YEAR:3-6-2005]Kagan,R.M., Shenderovich,M.D., Heseltine,P.N. and Ramnarayan,K.<br>Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir<br>Protein Sci (3-6-2005) 14, 1870-1878. PubMed  Europe PubMed DOI  PMC  EPMC  S  I
  30. Kaplan,S.S. and Hicks,C.B.<br>Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection<br>Expert Opin Pharmacother (2005) 6, 1573-1585. PubMed  Europe PubMed DOI  I
    31. 2004
  31. de Mendoza,C. and Soriano,V.<br>Resistance to HIV protease inhibitors: mechanisms and clinical consequences<br>Curr Drug Metab (2004) 5, 321-328. PubMed  Europe PubMed DOI  I
    32. 2002
  32. Corbett,A.H., Lim,M.L. and Kashuba,A.D.<br>Kaletra (lopinavir/ritonavir)<br>Ann Pharmacother (2002) 36, 1193-1203. PubMed  Europe PubMed  I
  33. de Mendoza,C., Martin-Carbonero,L., Barreiro,P., Diaz,B., Valencia,E., Jimenez-Nacher,I., Gallego,O., Nunez,M., Gonzalez-Lahoz,J. and Soriano,V.<br>Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families<br>HIV Clin Trials (2002) 3, 304-309. PubMed  Europe PubMed  I
  34. Qazi,N.A., Morlese,J.F. and Pozniak,A.L.<br>Lopinavir/ritonavir (ABT-378/r)<br>Expert Opin Pharmacother (2002) 3, 315-327. PubMed  Europe PubMed DOI  I
  35. [YEAR:4-11-2002]Sham,H.L., Zhao,C., Li,L., Betebenner,D.A., Saldivar,A., Vasavanonda,S., Kempf,D.J., Plattner,J.J. and Norbeck,D.W.<br>Novel lopinavir analogues incorporating non-aromatic P-1 side chains - synthesis and structure-activity relationships<br>Bioorg Med Chem Lett (4-11-2002) 12, 3101-3103. PubMed  Europe PubMed DOI  I
  36. [YEAR:22-4-2002]Sham,H.L., Betebenner,D.A., Chen,X., Saldivar,A., Vasavanonda,S., Kempf,D.J., Plattner,J.J. and Norbeck,D.W.<br>Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir)<br>Bioorg Med Chem Lett (22-4-2002) 12, 1185-1187. PubMed  Europe PubMed DOI  I
  37. Stoll,V., Qin,W., Stewart,K.D., Jakob,C., Park,C., Walter,K., Simmer,R.L., Helfrich,R., Bussiere,D., Kao,J., Kempf,D., Sham,H.L. and Norbeck,D.W.<br>X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease<br>Bioorg Med Chem (2002) 10, 2803-2806. PubMed  Europe PubMed DOI  S  I
    38. 2001
  38. Mangum,E.M. and Graham,K.K.<br>Lopinavir-Ritonavir: a new protease inhibitor<br>Pharmacotherapy (2001) 21, 1352-1363. PubMed  Europe PubMed  I
  39. [YEAR:4-6-2001]Sham,H.L., Betebenner,D.A., Herrin,T., Kumar,G., Saldivar,A., Vasavanonda,S., Molla,A., Kempf,D.J., Plattner,J.J. and Norbeck,D.W.<br>Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir)<br>Bioorg Med Chem Lett (4-6-2001) 11, 1351-1353. PubMed  Europe PubMed DOI  I
    40. 2000
  40. Hurst,M. and Faulds,D.<br>Lopinavir<br>Drugs (2000) 60, 1371-1379. PubMed  Europe PubMed  I
    41. 1998
  41. Sham,H.L., Kempf,D.J., Molla,A., Marsh,K.C., Kumar,G.N., Chen,C.M., Kati,W., Stewart,K., Lal,R., Hsu,A., Betebenner,D., Korneyeva,M., Vasavanonda,S., McDonald,E., Saldivar,A., Wideburg,N., Chen,X., Niu,P., Park,C., Jayanti,V., Grabowski,B., Granneman,G.R., Sun,E., Japour,A.J., Leonard,J.M., Plattner,J.J. and Norbeck,D.W.<br>ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease<br>Antimicrob Agents Chemother (1998) 42, 3218-3224. PubMed  Europe PubMed  PMC  EPMC  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use